US20100042168A1 - Electronic system for influencing cellular functions in a warm-blooded mammalian subject - Google Patents

Electronic system for influencing cellular functions in a warm-blooded mammalian subject Download PDF

Info

Publication number
US20100042168A1
US20100042168A1 US12/450,450 US45045008A US2010042168A1 US 20100042168 A1 US20100042168 A1 US 20100042168A1 US 45045008 A US45045008 A US 45045008A US 2010042168 A1 US2010042168 A1 US 2010042168A1
Authority
US
United States
Prior art keywords
frequencies
amplitude
amplitude modulation
frequency
control information
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/450,450
Other languages
English (en)
Inventor
Boris Pasche
Alexandre Barbault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THERABIONIC LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20100042168A1 publication Critical patent/US20100042168A1/en
Assigned to THERABIONIC, LLC reassignment THERABIONIC, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARBAULT, ALEXANDRE, MR., PASCHE, BORIS, MR.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment

Definitions

  • This invention relates to an electronic system for influencing cellular functions in a warm-blooded mammalian subject. More particularly, the invention concerns research findings related to how earlier electronic systems may be modified and programmed to achieve both improved and additional therapeutic effects.
  • the direct or indirect influence on cancerous cell growth may involve but is not necessarily limited to any of prophylactic avoidance of cancerous cell formation, influencing of cell functions such as for example influencing leukocyte cell functions which can lead to inhibition of cancerous cell growth or proliferation thereof, and/or killing of cancerous cells harboured by a warm-blooded mammalian subject.
  • Electromagnetic energy generating devices and use of electromagnetic energies for treating living mammalian subjects harbouring cancerous cells described in the literature include: U.S. Pat. No. 5,908,441 issued Jun. 1, 1999 to Bare; James E. and the references cited therein and so-called “NovoCure technology” involving in vivo implantation of electrodes to either side of tumorous growths.
  • This literature does not contemplate very low energy emissions of electromagnetic energy involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
  • U.S. Pat. No. 5,690,692 issued on Nov. 25, 1997 entitled “Bio-Active Frequency Generator and Method” describes a programmable control which instructs a frequency synthesizer to enable generation of an electrical current at a specific precise frequency signal or at a series of specific precise frequencies signals having a square wave form to within an accuracy of 0.001 Hz.
  • This Patent contemplates amplifying the voltage of the generated signals and applying the signals to a subject at the specific precise frequency or sequentially at the series of specific precise frequencies by means of electrodes held by or otherwise connected to the subject (which may be a mammal or a food).
  • this Patent does not contemplate very low energy emissions involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
  • an electronic system which is activatable by electrical power.
  • the system is employed to influence cellular functions or malfunctions in a warm-blooded mammalian subject.
  • the system comprises one or more controllable low energy electromagnetic energy generator circuits for generating one or more high frequency radio frequency RF carrier signals.
  • One or more microprocessors or integrated circuits comprising or communicating with the one or more generator circuits are provided which are also for receiving control information from a source of programmed control information.
  • the one or more generator circuits include one or more amplitude modulation control signal generators for controlling amplitude modulated variations of the one or more high frequency carrier signals.
  • the one or more generator circuits furthermore include one or more programmable amplitude modulation frequency control signal generators for controlling the frequency at which the amplitude modulations are generated.
  • the one or more amplitude modulation frequency control generators are, in terms of an important improvement of the present invention, adapted to accurately control the frequency of the amplitude modulations to within an accuracy of at least 1000 ppm relative to one or more determined or predetermined reference amplitude modulation frequencies selected from within a range of 0.01 Hz to 150 kHz.
  • the system furthermore comprises a connection or coupling position for connection or coupling to or being connected or coupled to an electrically conductive applicator for applying to the warm-blooded mammalian subject the one or more amplitude-modulated low energy emissions at said accurately controlled modulation frequencies.
  • the term, “accurately controlled” means that the modulated low energy electromagnetic emissions should be modulated to within a resolution of at most about 1 Hz of intended higher frequencies (greater than about 1000 Hz) determined or predetermined modulation frequencies. For example, if one of the one or more determined or predetermined modulation frequencies to be applied to the warm-blooded mammalian subject is about 2000 Hz, the accurate control should lead to such modulated low energy emission being generated at a frequency of between about 1999 and about 2001 Hz.
  • the accurate control should lead to a resolution of about 0.5, more preferably about 0.1, yet more preferably about 0.01 and indeed most preferably about 0.001 Hz of the intended determined or predetermined modulation frequency.
  • the specific absorption rate should be and is most preferably substantially less than 1.6 milliW/g weight of living tissue.
  • the system includes a microprocessor (which may more recently be replaced by an integrated circuit) into which control information is loaded from an application storage device.
  • the microprocessor (or now alternatively integrated circuit) then controls the function of the system to produce the desired therapeutic emissions.
  • an impedance transformer connected intermediate the emitter of low energy electromagnetic emissions and a probe (here more broadly described as an electrically conductive applicator) for applying the emissions to the patient.
  • the impedance transformer substantially matches the impedance of the patient seen from the emitter circuit with the impedance of the output of the emitter circuit.
  • FIG. 1 shows an exemplary casing structure for the electronic circuit shown in FIG. 2 , an applicator 13 (exemplified as a probe suitable for being placed in the mouth of a patient) and an interface 16 (which may be replaced by a receiver) for receiving information from a source of information 52 such as may be comprised in an information storage device, e.g. of the nature described and illustrated in FIGS. 12 to 17 of EP 0 592 851 B1.
  • a source of information 52 such as may be comprised in an information storage device, e.g. of the nature described and illustrated in FIGS. 12 to 17 of EP 0 592 851 B1.
  • FIG. 2 is a block diagram of exemplary circuitry which may be comprised in the exemplary casing structure of FIG. 1 .
  • This FIG. 2 differs essentially from FIG. 2 of EP 0 592 851 B1 by comprising a highly accurate modulation frequency generator 31 (named a Digital Direct Synthesizer or DDS), which enables accurate control of modulatable oscillator represented by dotted line block 106 .
  • DDS Digital Direct Synthesizer
  • FIG. 3 of EP 0 592 851 B1 is a detailed schematic of a modulation signal generator 31, replaced by a DDS modulation frequency generator 31 comprised in the circuit of present FIG. 2 ;
  • FIG. 4 of EP 0 592 851 B1 is a detailed schematic of a modulation signal buffer and carrier oscillator circuit which may be employed in the circuit of the present FIG. 2 ;
  • FIG. 5 of EP 0 592 851 B1 is a detailed schematic example of an amplitude modulation (AM) and power generator 34 and output filter 39 which could be comprised in the circuit of the present FIG. 2 ;
  • AM amplitude modulation
  • FIG. 6 of EP 0 592 851 B1 is a detailed schematic example of an impedance transformer 14 which may be comprised in the circuit of the present FIG. 2 ;
  • FIG. 7 of EP 0 592 851 B1 is a detailed schematic example of an emission sensor 53 which may be comprised in the circuit of the present FIG. 2 ;
  • FIG. 8 of EP 0 592 851 B1 is a detailed schematic example of an output power sensor circuit 54 which may be employed in the circuit of the present FIG. 2 .
  • FIG. 9 of EP 0 592 851 B1 is a detailed schematic example of a display module or information output 17 which may be included in the circuit of the present FIG. 2 .
  • FIG. 10 of EP 0 592 851 B1 is a detailed schematic example of a power supply control circuit including battery charger 57 which may be comprised in the circuit of the present FIG. 2 .
  • FIGS. 11a-d of EP 0 592 851 B1 are exemplary flow charts of the method of operation of the system of FIGS. 1 and 2 .
  • FIG. 1 presented is a modulated low energy electromagnetic emission application system 11 , in accordance with the present invention.
  • a modulated low energy electromagnetic emission application system 11 As described in prior U.S. Pat. Nos. 4,649,935 and 4,765,322, such a system has proven to be useful in the practice of Low Energy Emission Therapy (LEET, a trademark of Symtonic S.A. or a successor of this Company), which involves application of emissions of low energy radio frequency (RF) electromagnetic waves to a warm-blooded mammalian subject.
  • LEET Low Energy Emission Therapy
  • RF radio frequency
  • the application has proven to be an effective mode of treating a warm-blooded mammalian subject suffering from central nervous system (CNS) disorders such as, for example, generalized anxiety disorders, panic disorders, sleep disorders including insomnia, psychiatric disorders such as depression, obsessive compulsive disorders, disorders resulting from substance abuse, sociopathy, post traumatic stress disorders or other disorders of the central nervous system and combinations thereof.
  • CNS central nervous system
  • the system includes an electrically conductive applicator 12 , 13 for applying one or more electromagnetic emissions to the warm-blooded mammalian subject.
  • One form of applicator may consist of an electrically conductive probe or mouthpiece 13 which is inserted into the mouth of a subject undergoing treatment. Probe 13 is connected to an electromagnetic energy emitter (see also FIG. 2 ), through coaxial cable 12 and impedance matching transformer 14 .
  • An example of a coupling found to be effective involving indirect physical contact with the skin of a patient is an insulated applicator to be placed over or within an ear of the patient.
  • the emissions thus passed to the patient may be either by capacitive or radiated means or by a combination of both.
  • Electronic system 11 also includes a connector or coupler for connection to a programmable device such as a computer or an interface or receiver 16 which is adapted to receive an application storage device 52 such as, for example, magnetic media, semiconductor media, optical media or mechanically encoded media, or programmed emissions programmed with control information employed to control the operation of system 11 so that the desired type of low energy emission therapy is applied to the patient.
  • a programmable device such as a computer or an interface or receiver 16 which is adapted to receive an application storage device 52 such as, for example, magnetic media, semiconductor media, optical media or mechanically encoded media, or programmed emissions programmed with control information employed to control the operation of system 11 so that the desired type of low energy emission therapy is applied to the patient.
  • Application storage device 52 can be provided with a microprocessor which, when applied to interface 16 , operates to control the function of system 11 to apply the desired low energy emission therapy.
  • application storage device 52 can be provided with a microprocessor which is used in combination with microprocessor 21 within system 11 .
  • the microprocessor within device 52 could assist in the interfacing of storage device 52 with system 11 , or could provide security checking functions.
  • System 11 may also include a display 17 which can display various indications of the operation of system 11 .
  • system 11 may include on and off power buttons 18 and 19 , optionally replaced by user interface 21 A (refer to FIG. 2 ).
  • FIG. 2 presented is a block diagram of exemplary electronic circuitry of system 11 , in accordance with the present invention.
  • a data processor such as for example, microprocessor or integrated circuit 21 , operates as the controller for electronic system 11 , and is connected to control the various components of the system 11 , for example, through address bus 22 , data bus 23 and input/output lines 25 .
  • the block diagram of FIG. 2 is modified as compared to FIG. 2 of EP 0 592 851 B1 by including what is known as a digital direct synthesizer (DDS) 31 which operates as a accurate and stable modulation frequency generator within the system 11 .
  • DDS digital direct synthesizer
  • An exemplary DDS device is available from Analog Devices of Norwood, Mass. 02062-9106, USA, Part No AD9835.
  • the device is a numerically controlled oscillator and modulation capabilities are provided for phase modulation and frequency modulation.
  • dotted line block 102 entitled “PROCESSOR WITH DAC”, the functionality of the DDS may also be combined with microprocessor 21 with digital to analogue converter (DAC).
  • DAC digital to analogue converter
  • Microprocessor 21 preferably includes internal storage for the operation of a coded control program, and temporary data.
  • microprocessor 21 may include input/output ports and internal timers.
  • Microprocessor 21 may be a microcontroller, for example microcontrollers 8048 or 8051 available from Intel Corporation of Santa Clara, Calif. 95054-1549, USA.
  • microprocessor 21 The timing for microprocessor 21 is provided by system clock oscillator 26 A which may be run at any clock frequency suitable for the particular type of microprocessor used.
  • An exemplary clock frequency is about 8.0 MHz.
  • Oscillator 26 A may be replaced by reference frequency oscillator 26 which secures the stability of the accurate modulation frequency.
  • RF (radio frequency) oscillator 32 may also be employed for this purpose.
  • a combination of oscillators is represented by dotted line block 104 , entitled “OSCILLATOR”.
  • microprocessor 21 functions to control controllable electromagnetic energy generator circuit 29 to produce a desired form of modulated low energy electromagnetic emission for application to a subject through applicator or probe 13 .
  • Dotted line block 29 entitled CONTROLLABLE GENERATOR, includes DDS modulation frequency generator 31 and carrier signal oscillator 32 .
  • Microprocessor 21 operates to activate or deactivate controllable generator circuit 29 through oscillator disable line 33 , as described in greater detail in EP 0 592 851 B1.
  • Controllable generator circuit 29 also includes an AM modulator and power generator 34 which operates to amplitude modulate a carrier signal produced by carrier oscillator 32 on carrier signal line 36 , with a modulation signal produced by modulation signal generator circuit 31 on modulation signal line 37 .
  • the combination of the functionality of the DDS modulation frequency generator 31 , with processor 21 with DAC, represented by dotted line block 102 enables output lines 33 and 37 to be combined to produce a single signal. The combination furthermore enables arbitrary or periodic wave forms of any shape to be generated, as similarly described in EP 0 592 851 B1.
  • AM modulator and power generator 34 produces an amplitude modulated carrier signal on modulated carrier signal line 38 , which is then applied to emitter output filter circuit 39 .
  • the filter circuit 39 is connected to probe or applicator 13 via power emission sensor 54 , coaxial cable 12 and impedance transformer 14 .
  • Microprocessor 21 controls DDS modulation signal generator circuit 31 of controllable generator circuit 29 via interface lines 25 .
  • microprocessor 21 may select a desired waveform stored in a modulation waveform storage device 43 and also controls a waveform address generator 41 to produce on waveform address bus 42 a sequence of addresses which are applied to modulation signal storage device 43 in order to retrieve the selected modulation signal.
  • the desired modulation signal is retrieved from modulation signal storage device 43 and applied to modulation signal bus 44 in digital form.
  • Modulation signal bus 44 is applied to wave form generator and DAC 46 which converts the digital modulation signal into analogue form.
  • This analogue modulation signal is then applied to a selective filter 47 which, under control of microprocessor 21 , filters the analogue modulation signal by use of a variable filter network including resistor 48 and capacitors 49 and 51 in order to smooth the wave form produced by DAC 46 on modulation signal line 20 .
  • a further embodiment possibility is a combination of PROCESSOR WITH DAC dotted line block 102 with OSCILLATOR dotted line block 104 or with a combination of oscillators 26 and 26 A.
  • the hardware solution described in EP 0 592 851 B1 can be realized internally in the processor 102 with multiple outputs 33 and 37 or a single output combining these signals.
  • the particular modulation control information employed by microprocessor 21 to control the operation of controllable generator circuit 29 is stored in application storage device 52 .
  • the application storage device is conveniently a computer comprising or being for receiving the information.
  • application storage devices illustrated and described in EP 0 592 851 B1, with reference to FIGS. 12, 13, 14 and 15, may be selected.
  • Interface 16 is configured as appropriate for the particular application storage device 52 in use. Interface 16 translates the control information stored in application storage device 52 into a usable form for storage within the memory of microprocessor 21 to enable microprocessor 21 to control controllable generator circuit 29 to produce the desired modulated low energy emission.
  • Interface 16 may directly read the information stored on application storage device 52 , or it may read the information through use of various known communication links. For example, radio frequency, microwave, laser, telephone, internet or optical based communications links may be employed to transfer information between interface or receiver 16 and application storage device or computer 52 .
  • the system 11 may comprise a user identification device, included in block 21 a in FIG. 2 . Conveniently, such a device communicates with the one or more data processors or integrated circuits 21 via interface 16 , as shown.
  • the user identification device may be of any type, a finger print reader being an example. Such a reader is for example available from Lenovo, 70563 Stuttgart, Germany, Part No. 73P4774.
  • control information stored in application storage device or computer 52 specifies various controllable parameters of the modulated low energy RF electromagnetic emission to be applied to a subject through applicator or probe 13 .
  • controllable parameters include, for example, but are not necessarily limited to, the frequency and amplitude of the carrier, the amplitudes and frequencies and wave forms of the modulation of the carrier, the duration of the emission, the power level of the emission, the duty cycle of the emission (i.e., the ratio of on time to off time of pulsed emissions applied during a treatment), the sequence of application of different modulation frequencies for a particular application, and the total number of treatments and duration of each treatment prescribed for a particular subject, and combinations thereof.
  • the carrier signal and modulation signal may be selected to drive the applicator or probe 13 with an amplitude modulated signal in which the carrier signal includes spectral frequency components below about 1 GHz, and preferably between about 1 MHz and about 900 MHz, and in which the modulation signal comprises spectral frequency components between about 0.01 Hz and 150 KHz.
  • the one or more modulation frequencies may be simultaneously emitted or sequenced to form the modulation signal.
  • an electromagnetic emission sensor 53 may be provided to detect the presence of electromagnetic emissions at the frequency of the carrier oscillator 32 .
  • Emission sensor 53 provides microprocessor 21 with an indication of whether or not electromagnetic emissions at the desired frequency are present.
  • Microprocessor 21 then takes appropriate action, for example, by displaying an error message on display 17 , disabling controllable generator circuit 29 , or the like.
  • a power sensor 54 is preferably included which detects the amount of power applied to the subject through applicator or probe 13 compared to the amount of power returned or reflected from the subject. This ratio is indicative of the proper use of the system during a therapeutic session. Power sensor 54 applies to microprocessor 21 , through power sensor line 56 , an indication of the amount of power applied to patient through applicator or probe 13 relative to the amount of power reflected from the patient.
  • the indication provided on power sense line 56 may be digitalized and employed by microprocessor 21 , for example, to detect and control a level of applied power, and to record on application storage device 52 information related to the actual treatments applied to and received by the patient. Such information may then be used by a physician or other clinician to assess patient treatment compliance and effect.
  • treatment information may include, for example: the number of treatments applied for a given time period; the actual time and date of each treatment; the number of attempted treatments; the treatment compliance (i.e., whether the applicator or probe was in place or not during the treatment session); and the cumulative dose of a particular modulation frequency.
  • the level of power applied is preferably controlled to cause the specific absorption rate (SAR) of energy absorbed by the patient to be from about 1 microWatt per kilogram of tissue to about 50 Watts per kilogram of tissue.
  • the power level is controlled to cause an SAR of from about 100 microWatts per kilogram of tissue to about 10 Watts per kilogram of tissue.
  • the power level is controlled to cause an SAR of from about 1 milliWatt per kilogram of tissue to about 100 milliWatts per kilogram of tissue.
  • SARs may be in any tissue of the patient, but are preferably in the tissue of the central nervous system or the diseased tissue.
  • System 11 may also include powering circuitry including battery and charger circuit 57 and battery voltage change detector 58 .
  • the RF carrier oscillator 32 produces a RF carrier frequency of about 27 MHz.
  • Other embodiments of the invention contemplate RF carrier frequencies of about 48 MHz, about 433 MHz or about 900 MHz.
  • the RF carrier frequency produced by carrier oscillator 32 has spectral frequency components less than about 1 GHz and preferably between about 1 MHz and about 916 MHz.
  • the carrier frequency produced by carrier oscillator 32 may be variable and controllable by microprocessor 21 by use of stored or transmitted control information.
  • Carrier oscillator 32 produces on carrier signal line 36 a carrier signal which is then modulated by the modulation signal carried on signal line 37 .
  • Oscillator disable line 33 enables microprocessor 21 to disable the signal from oscillator 32 by applying an appropriate disable signal to oscillator disable line 33 .
  • the output of the AM modulator and power generator 34 appears on signal line 38 .
  • This modulated signal is applied through emitter output filter 39 which substantially reduces or eliminates the carrier harmonics resulting from side effects of the modulator and power generator circuit 34 .
  • the output of the AM modulator and power generator 34 and emitter output filter 39 may be designed to possess a 50 Ohm output impedance to match a 50 Ohm impedance of coaxial cable 12 .
  • Impedance transformer 14 serves to match this complex impedance with the 50 Ohm impedance of coaxial cable 12 and therefore the output impedance of the AM modulator 34 and output filter 39 . This promotes power transmission, and minimizes reflections.
  • a contact probe with coupling to the mucosa of the mouth has been optimized for a contact probe with coupling to the mucosa of the mouth.
  • a conductive, isolated probe has been used at a frequency around 433 MHz coupling to the outer ear channel. Due to the different probe design in such a frequency band and with this coupling method, the values of matching elements (79 and 81 described in EP 0592 851 B1) would be different or could even be omitted.
  • Applicator or probe 13 may then be regarded as a capacitive coupler or as an antenna matched to the capacitive load.
  • microprocessor 21 may operate to analyse the signal appearing on power sense line 56 to determine and control the amount of power applied to the patient, and to assess patient treatment compliance, and possibly to record indicia of the patient treatment compliance on application storage device 52 for later analysis and assessment by a physician or other clinician.
  • Exemplary of treatments performed on patients have included brain, bladder, colorectal, kidney, mesothelium, neuroendocrine, liver, lung, breast, ovary, pancreas, prostate and thyroid tumour types.
  • the treatments involved applying an about 27.12 MHz RF signal, amplitude modulated at specifically defined frequencies ranging from about 0.2 to about 23,000 Hz at very high precision and stability. Further Examples of treatment modes (at specific accurately controlled AM frequencies) for specified types of tumours are described in detail below.
  • a phase I study was conducted consisting of three daily 40 min treatments. From March 2004 to September 2006, 24 patients with advanced solid tumors were enrolled. The median age was 57.0 ⁇ 12.2 years. 16 patients were female. As of January 2007, 5 patients are still on therapy, 13 patients died of tumor progression, 2 patients are lost to follow-up and one patient withdrew consent. The most common tumor types were breast (7), ovary (5) and pancreas (3). 22 patients had received prior systemic therapy and 16 had documented tumor progression prior to study entry.
  • patients with progressive disease at study entry one had a partial response for >14.4 weeks associated with >50% decrease in CEA, CA 125 and CA 15-3 (previously untreated metastatic breast cancer); one patient had stable disease for 34.6 weeks (add info); one patient had a 50% decrease in CA 19-9 for 12.4 weeks (recurrent pancreatic cancer).
  • Phase I data suggest that low levels of electromagnetic fields amplitude-modulated at specific frequencies administered intrabucally with the device of Example A are a safe and potentially effective treatment for advanced cancer.
  • the device emits a 27.12 MHz RF signal, amplitude-modulated with cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision.
  • the device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced hepatocellular carcinoma HCC and limited therapeutic options were offered treatment with a combination of HCC-specific frequencies.
  • the electronic device of the present invention comprising means for the accurate control over the frequencies and stability of amplitude modulations of a high frequency carrier signal, provides a safe and promising novel treatment modality for the treatment of patients suffering from various types of advanced forms of cancer.
  • Exemplary of above accurately controlled amplitude modulated frequencies controlling the frequency of amplitude modulations of a high frequency carrier signal are set forth below along with the type of cancer or tumour harboured by a subject to be treated.
  • the above Examples reflect AM frequencies determined by a bio-feedback procedure involving very substantial observations and measurements of physiological responses (at certain well defined AM frequencies) by subjects exposed to low energy electromagnetic emission excitation. In general, it is recommended that all of the listed frequencies be applied in the treatment of subjects suffering from the indicated form of cancer. However, a limited number of the listed frequencies also lead to beneficial effects.
  • the electronic system of the present invention may be adapted to screen a subject for physiological responses over a broad range of frequencies to determine the presence or absence tumour cells and, if positive, then to note at which defined frequencies physiological responses are elicited.
  • These frequencies will in general match with the defined frequencies listed in one or other of the Examples above or such further examples as may be developed and hence the nature of the tumour will be known.
  • the electronic system of the invention is therefore a valuable diagnostic tool for diagnosing the presence or absence and identities of types of tumour cell growths or cancers. Furthermore, the electronic system of the invention is of value for predicting whether a patient will benefit from the application of a given series of modulation frequencies. The system therefore possesses a capability of predicting responses to treatment, thereby enhancing the possibility to select optimal modes of treatment.
  • the sequence of well defined frequencies are preferably applied sequentially for determined periods of time, e.g. 3 seconds for each frequency, but several frequencies may also be applied simultaneously. This means that a cycle of application involving 180 frequencies would take nearly 10 minutes time. Advantageous effects may however also arise from applying individual well defined frequencies for differing time periods, e.g. some for 3 seconds, some for 6 seconds, etc. . . . .
  • Therapeutic dosages to be applied to a subject suffering from the presence of tumour cell growth or cancer are determined by the time of application of the low energy electromagnetic emissions to the subject and will depend on the nature of the cancer and the overall condition of the subject. In general, however, greatest experience has been gained in treating terminally ill subjects expected to survive no longer than about three months and who have agreed to discontinue alternative forms of cancer treatments such as chemo-therapy or radioactive treatment. In these severe cases, lengthy times of treatment are recommended, e.g. 3 times 1 hour daily treatment.
  • alternative forms of application i.e. other than by means of a mouth probe, continuous application is possible and is likely to enhance compliance and the efficacy of the treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Magnetic Treatment Devices (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Current-Collector Devices For Electrically Propelled Vehicles (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
US12/450,450 2007-03-27 2008-03-26 Electronic system for influencing cellular functions in a warm-blooded mammalian subject Abandoned US20100042168A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07006320A EP1974769A1 (en) 2007-03-27 2007-03-27 Electronic system for influencing cellular functions in a warm-blooded mammalian subject
EP07006320.1 2007-03-27
PCT/EP2008/002379 WO2008116640A2 (en) 2007-03-27 2008-03-26 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Publications (1)

Publication Number Publication Date
US20100042168A1 true US20100042168A1 (en) 2010-02-18

Family

ID=38117246

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/450,450 Abandoned US20100042168A1 (en) 2007-03-27 2008-03-26 Electronic system for influencing cellular functions in a warm-blooded mammalian subject
US13/573,104 Active 2030-03-12 US8977365B2 (en) 2007-03-27 2012-08-22 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/573,104 Active 2030-03-12 US8977365B2 (en) 2007-03-27 2012-08-22 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Country Status (20)

Country Link
US (2) US20100042168A1 (ja)
EP (2) EP1974769A1 (ja)
JP (1) JP5435240B2 (ja)
KR (1) KR101474582B1 (ja)
CN (1) CN101663065B (ja)
AU (1) AU2008232041C1 (ja)
BR (1) BRPI0810084B1 (ja)
CA (1) CA2682322C (ja)
DK (1) DK2139557T3 (ja)
ES (1) ES2545103T3 (ja)
HU (1) HUE027033T2 (ja)
IL (1) IL201099A (ja)
MX (1) MX2009010425A (ja)
PL (1) PL2139557T3 (ja)
PT (1) PT2139557E (ja)
RU (1) RU2594824C2 (ja)
SA (1) SA08290168B1 (ja)
SI (1) SI2139557T1 (ja)
WO (1) WO2008116640A2 (ja)
ZA (1) ZA200906700B (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120310033A1 (en) * 2009-12-23 2012-12-06 Axel Muntermann Method for Cosmetic Skin Smoothening and Device Therefor
WO2014164924A1 (en) * 2013-03-11 2014-10-09 NeuroEM Therapeutics, Inc. Electromagnetic treatment of brian and body disorders
ES2535696A1 (es) * 2013-11-13 2015-05-13 Joaquín SUROS FRIGOLA Generador de ondas de AM y FM para la práctica de la electroterapia
WO2019075391A1 (en) 2017-10-13 2019-04-18 Costa Frederico Perego SYSTEM FOR CHARACTERIZING, DIAGNOSING AND PROCESSING A PATIENT'S HEALTH STATUS AND MICROTUBULAR CONDUCTIVITY, AND METHODS OF USING THE SAME
US20190217111A1 (en) * 2013-03-11 2019-07-18 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
CN110248696A (zh) * 2017-07-21 2019-09-17 耀姿玛碧艾姆科技有限公司 口腔用高频治疗仪
US11752356B2 (en) 2013-03-11 2023-09-12 NeuroEM Therapeutics, Inc. Systems for controlling power to differently loaded antenna arrays
US11759650B2 (en) 2013-03-11 2023-09-19 NeuroEM Therapeutics, Inc. Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment
US11794028B2 (en) 2014-03-11 2023-10-24 NeuroEM Therapeutics, Inc. Transcranial electromagnetic treatment
US11911629B2 (en) 2013-03-11 2024-02-27 NeurEM Therapeutics, Inc. Treatment of primary and metastatic brain cancers by transcranial electromagnetic treatment

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
ITPD20090279A1 (it) * 2009-09-25 2011-03-26 Hypothesis Srl Dispositivo per la prevenzione della trombosi venosa profonda
WO2012143667A2 (en) * 2011-04-18 2012-10-26 Freewave Ltd Therapeutic apparatus
WO2012030248A1 (ru) * 2010-09-03 2012-03-08 Sajphutdinov Marat Kadirovich Система электромагнитной бесконтактной терапии
ITBO20110125A1 (it) * 2011-03-16 2012-09-17 Project Di Gaudenzi Valter Dispositivo per applicazioni al corpo
ITNA20110019A1 (it) * 2011-04-28 2012-10-29 Attilio Grattacaso Apparecchiatura, sistema e metodo per la contrazione e la congiunta diatermia mediante modulazione e radiofrequenza
CN102353848B (zh) * 2011-07-01 2013-08-28 大连海事大学 一种细胞用电磁辐射实验系统
RU2514344C1 (ru) * 2012-12-05 2014-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СамГМУ Минздрава России) Способ вестибулопластики
US9784263B2 (en) 2014-11-06 2017-10-10 Zoll Circulation, Inc. Heat exchange system for patient temperature control with easy loading high performance peristaltic pump
US11359620B2 (en) 2015-04-01 2022-06-14 Zoll Circulation, Inc. Heat exchange system for patient temperature control with easy loading high performance peristaltic pump
US20160317050A1 (en) 2015-04-28 2016-11-03 Federico Perego Costa Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
US11116657B2 (en) 2017-02-02 2021-09-14 Zoll Circulation, Inc. Devices, systems and methods for endovascular temperature control
US11185440B2 (en) 2017-02-02 2021-11-30 Zoll Circulation, Inc. Devices, systems and methods for endovascular temperature control
US11071876B2 (en) * 2018-12-03 2021-07-27 Aah Holdings Llc Apparatus and method for treatment of mental and behavioral conditions and disorders with electromagnetic fields
BR112021020351A2 (pt) 2019-04-10 2021-12-07 Autem Medical Llc Sistema para prognosticar um resultado em um paciente, método para prognosticar uma condição de saúde de um paciente e método para prognosticar um resultado associado a um paciente
CN114786608A (zh) * 2019-10-21 2022-07-22 仿生治疗股份有限公司 用于治疗受试者的电气系统
CA3163248A1 (en) 2019-12-11 2021-06-17 Novocure Gmbh Compositions and methods for imaging a cell
WO2021116753A1 (en) 2019-12-11 2021-06-17 Novocure Gmbh Methods of altering the electric impedance to an alternating electric field
WO2021116754A2 (en) 2019-12-11 2021-06-17 Novocure Gmbh Compositions and methods of altering the electric impedance to an alternating electric field
EP4146327A1 (en) 2020-05-08 2023-03-15 Novocure GmbH Compositions and methods of applying alternating electric fields to pluripotent stem cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649935A (en) * 1984-05-21 1987-03-17 Symtonic Sa Method of treating neurovegetative disorders and apparatus therefor
US5441528A (en) * 1992-09-25 1995-08-15 Symtonic, S.A. Method and system for applying low energy emission therapy
US5690692A (en) * 1995-10-11 1997-11-25 Regeneration Technology Bio-active frequency generator and method
US5908441A (en) * 1997-01-16 1999-06-01 Bare; James E. Resonant frequency therapy device
US6167304A (en) * 1993-05-28 2000-12-26 Loos; Hendricus G. Pulse variability in electric field manipulation of nervous systems
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07171222A (ja) * 1993-12-21 1995-07-11 Olympus Optical Co Ltd 温熱治療装置
RU2112563C1 (ru) * 1995-03-14 1998-06-10 Синицын Лев Николаевич Способ лечения гнойных ран
US5891182A (en) * 1995-10-11 1999-04-06 Regeneration Tech Bio-active frequency generator and method
US6246912B1 (en) * 1996-06-27 2001-06-12 Sherwood Services Ag Modulated high frequency tissue modification
RU2127616C1 (ru) * 1998-02-03 1999-03-20 Закрытое акционерное общество НЦИМ "ЛИДО" Устройство для миллиметрововолновой терапии
EP0966988A1 (en) * 1998-06-24 1999-12-29 Santi Tofani Apparatus and method for interfering with pathological cells survival
US6530630B2 (en) * 2001-07-13 2003-03-11 Carrier Corporation Panel seal for an air handling unit
JP4664661B2 (ja) * 2004-12-15 2011-04-06 株式会社東芝 放射線治療管理システム

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649935A (en) * 1984-05-21 1987-03-17 Symtonic Sa Method of treating neurovegetative disorders and apparatus therefor
US4765322A (en) * 1984-05-21 1988-08-23 Symtonic Sa Method of treating neurovegetative disorders and apparatus therefor
US5441528A (en) * 1992-09-25 1995-08-15 Symtonic, S.A. Method and system for applying low energy emission therapy
US6167304A (en) * 1993-05-28 2000-12-26 Loos; Hendricus G. Pulse variability in electric field manipulation of nervous systems
US5690692A (en) * 1995-10-11 1997-11-25 Regeneration Technology Bio-active frequency generator and method
US5908441A (en) * 1997-01-16 1999-06-01 Bare; James E. Resonant frequency therapy device
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643026B2 (en) * 2009-12-23 2017-05-09 Axel Muntermann Method for cosmetic skin smoothening and device therefor
US20120310033A1 (en) * 2009-12-23 2012-12-06 Axel Muntermann Method for Cosmetic Skin Smoothening and Device Therefor
US11759650B2 (en) 2013-03-11 2023-09-19 NeuroEM Therapeutics, Inc. Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment
US20190217111A1 (en) * 2013-03-11 2019-07-18 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
US10765879B2 (en) 2013-03-11 2020-09-08 NeuroEM Therapeutics, Inc. Electromagnetic treatment of brain and body disorders
US11752356B2 (en) 2013-03-11 2023-09-12 NeuroEM Therapeutics, Inc. Systems for controlling power to differently loaded antenna arrays
WO2014164924A1 (en) * 2013-03-11 2014-10-09 NeuroEM Therapeutics, Inc. Electromagnetic treatment of brian and body disorders
US11813472B2 (en) * 2013-03-11 2023-11-14 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
US11911629B2 (en) 2013-03-11 2024-02-27 NeurEM Therapeutics, Inc. Treatment of primary and metastatic brain cancers by transcranial electromagnetic treatment
ES2535696A1 (es) * 2013-11-13 2015-05-13 Joaquín SUROS FRIGOLA Generador de ondas de AM y FM para la práctica de la electroterapia
US11794028B2 (en) 2014-03-11 2023-10-24 NeuroEM Therapeutics, Inc. Transcranial electromagnetic treatment
CN110248696A (zh) * 2017-07-21 2019-09-17 耀姿玛碧艾姆科技有限公司 口腔用高频治疗仪
WO2019075391A1 (en) 2017-10-13 2019-04-18 Costa Frederico Perego SYSTEM FOR CHARACTERIZING, DIAGNOSING AND PROCESSING A PATIENT'S HEALTH STATUS AND MICROTUBULAR CONDUCTIVITY, AND METHODS OF USING THE SAME

Also Published As

Publication number Publication date
US8977365B2 (en) 2015-03-10
SA08290168B1 (ar) 2013-04-30
CN101663065A (zh) 2010-03-03
EP1974769A1 (en) 2008-10-01
KR20100015970A (ko) 2010-02-12
CA2682322A1 (en) 2008-10-02
WO2008116640A3 (en) 2008-11-27
US20130079853A1 (en) 2013-03-28
ZA200906700B (en) 2010-11-24
AU2008232041C1 (en) 2014-02-20
CN101663065B (zh) 2014-04-16
WO2008116640A2 (en) 2008-10-02
BRPI0810084B1 (pt) 2016-04-12
DK2139557T3 (en) 2015-08-10
PT2139557E (pt) 2015-09-23
RU2594824C2 (ru) 2016-08-20
SI2139557T1 (sl) 2015-10-30
MX2009010425A (es) 2009-12-14
CA2682322C (en) 2015-07-14
JP2010522051A (ja) 2010-07-01
AU2008232041A2 (en) 2010-03-25
IL201099A0 (en) 2010-05-17
EP2139557B1 (en) 2015-05-13
ES2545103T3 (es) 2015-09-08
JP5435240B2 (ja) 2014-03-05
RU2009139633A (ru) 2011-05-10
PL2139557T3 (pl) 2015-10-30
EP2139557A2 (en) 2010-01-06
IL201099A (en) 2014-05-28
BRPI0810084A2 (pt) 2014-03-18
HUE027033T2 (en) 2016-08-29
AU2008232041B2 (en) 2013-11-14
AU2008232041A1 (en) 2008-10-02
KR101474582B1 (ko) 2014-12-19

Similar Documents

Publication Publication Date Title
US8977365B2 (en) Electronic system for influencing cellular functions in a warm-blooded mammalian subject
JP5840774B2 (ja) 埋込可能な医学治療送達装置のファーフィールド放射電力供給
CN108064147B (zh) 用于诊断患者的健康状况的血流动力学参数（hdp）监视系统
US6142927A (en) Method and apparatus for treatment with resonant signals
Habibagahi et al. Vagus nerve stimulation using a miniaturized wirelessly powered stimulator in pigs
US20220379130A1 (en) Electrical system for treatment of a subject
OA20699A (en) Electrical system for treatment of a subject
RU2139114C1 (ru) Устройство для лечения новообразований, вирусных и бактериальных заболеваний
RU2799358C2 (ru) Способы и устройства для эстетической терапии биологических структур с помощью радиочастотной и магнитной энергии
RU2134597C1 (ru) Устройство для микроволновой терапии
JP2001517975A (ja) 治療用装置及び方法
Levendag et al. Interstitial radiation and/or interstitial hyperthermia for advanced and/or recurrent cancers in the head and neck: a pilot study
Urbina et al. Electromagnetic Susceptibility of Implan table Medical Devices: An Experimental Assessment
CN109806502A (zh) 一种心脏内科理疗装置
RU2295988C2 (ru) Способ электромагнитотерапии и устройство для его осуществления
RU2279900C2 (ru) Способ электромагнитотерапии

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: THERABIONIC, LLC, ALABAMA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PASCHE, BORIS, MR.;BARBAULT, ALEXANDRE, MR.;SIGNING DATES FROM 20140209 TO 20140210;REEL/FRAME:032179/0915